Literature DB >> 3104480

In vivo administration of interleukin 1 to normal mice depresses their capacity to elicit contact hypersensitivity responses: prostaglandins are involved in this modification of immune function.

B Robertson, L Gahring, R Newton, R Daynes.   

Abstract

The administration of pyrogenic doses of interleukin 1 (IL-1) to normal mice before contact sensitization with dinitrofluorobenzene (DNFB) resulted in a significant reduction in the intensity of the elicited contact hypersensitivity (CH) responses. Adoptive transfer experiments established no difference between normal and IL-1-pretreated mice regarding their capacity to generate splenic suppressor-cell activity and lymph node effector-cell activity in response to DNFB. However, a marked reduction in the intensity of elicited responses was observed when primed CH-effector cells, obtained from normal donors, were adoptively transferred to IL-1-pretreated recipients. This finding was paralleled by a consistent reduction in the ability of the adoptively transferred cells to infiltrate the tissue sites of antigen challenge in the IL-1-pretreated animals. Treatment of mice with indomethacin, a potent inhibitor of prostaglandin production, abrogated the capacity of IL-1 to depress CH responses following skin sensitization with DNFB. Similarly, indomethacin was also capable of abrogating the ability of IL-1 to depress CH responses of adoptive recipients of primed CH-effector cells. Our results indicate that the capacity of IL-1 to depress CH responses in normal mice is due to an indomethacin-sensitive process, presumably mediated through the IL-1-induced generation and action of prostaglandins. This was supported by our finding that treatment of mice with arachidonic acid or prostaglandin E2 caused a similar type of inhibition. The mechanism(s) responsible for this effect appears to act at the efferent level of the CH response, as evidenced by the reduced capacity of CH-effector cells to infiltrate the tissue sites of antigen challenge.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3104480     DOI: 10.1111/1523-1747.ep12469071

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  8 in total

Review 1.  Keratinocyte-derived tumor necrosis factor and the physiopathology of the skin.

Authors:  P F Piguet
Journal:  Springer Semin Immunopathol       Date:  1992

Review 2.  Tumor necrosis factor and immunopathology.

Authors:  P F Piguet; G E Grau; P Vassalli
Journal:  Immunol Res       Date:  1991       Impact factor: 2.829

Review 3.  Contact dermatitis. Clinical perspectives and basic mechanisms.

Authors:  A Nasir; A A Gaspari
Journal:  Clin Rev Allergy Immunol       Date:  1996       Impact factor: 8.667

4.  Lipopolysaccharide from Escherichia coli reduces antigen-induced bronchoconstriction in actively sensitized guinea pigs.

Authors:  E Vannier; J Lefort; A Lellouch-Tubiana; B Terlain; B B Vargaftig
Journal:  J Clin Invest       Date:  1991-06       Impact factor: 14.808

5.  Genetic basis of the effects of ultraviolet light B on cutaneous immunity. Evidence that polymorphism at the Tnfa and Lps loci governs susceptibility.

Authors:  T Yoshikawa; J W Streilein
Journal:  Immunogenetics       Date:  1990       Impact factor: 2.846

6.  Characterization of the immunogenetic basis of ultraviolet-B light effects on contact hypersensitivity induction.

Authors:  I Kurimoto; J W Streilein
Journal:  Immunology       Date:  1994-03       Impact factor: 7.397

7.  Interleukin 1 suppresses inflammation in rabbit colitis. Mediation by endogenous prostaglandins.

Authors:  F Cominelli; C C Nast; R Llerena; C A Dinarello; R D Zipser
Journal:  J Clin Invest       Date:  1990-02       Impact factor: 14.808

8.  Identification of the molecular target for the suppression of contact hypersensitivity by ultraviolet radiation.

Authors:  L A Applegate; R D Ley; J Alcalay; M L Kripke
Journal:  J Exp Med       Date:  1989-10-01       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.